396 related articles for article (PubMed ID: 31739115)
1. New therapeutic targets in pancreatic cancer.
Lai E; Puzzoni M; Ziranu P; Pretta A; Impera V; Mariani S; Liscia N; Soro P; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Pireddu A; Demurtas L; Pusceddu V; Camera S; Sclafani F; Scartozzi M
Cancer Treat Rev; 2019 Dec; 81():101926. PubMed ID: 31739115
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
4. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
5. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
Manji GA; Olive KP; Saenger YM; Oberstein P
Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
[TBL] [Abstract][Full Text] [Related]
6. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract][Full Text] [Related]
7. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
8. Promising new therapies in advanced pancreatic adenocarcinomas.
Kundranda M; Kachaamy T
Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.
Chiorean EG; Coveler AL
Drug Des Devel Ther; 2015; 9():3529-45. PubMed ID: 26185420
[TBL] [Abstract][Full Text] [Related]
10. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
12. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.
Ho WJ; Jaffee EM; Zheng L
Nat Rev Clin Oncol; 2020 Sep; 17(9):527-540. PubMed ID: 32398706
[TBL] [Abstract][Full Text] [Related]
13. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
14. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
17. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
18. What treatment in 2017 for inoperable pancreatic cancers?
Taieb J; Pointet AL; Van Laethem JL; Laquente B; Pernot S; Lordick F; Reni M
Ann Oncol; 2017 Jul; 28(7):1473-1483. PubMed ID: 28459988
[TBL] [Abstract][Full Text] [Related]
19. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
20. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
